Abstract
Among all existing alpha emitting radionuclides, Actinium-225 (Ac-225), Astatine-211 (At-211), Bismuth-212 (Bi-212), Bismuth-213 (Bi-213), Lead-212 (Pb-212), Radium-223 (Ra-223), Terbium-149 (Tb-149) and Thorium-227 (Th-227) are notable radionuclides with potential therapeutic application in targeted alpha therapy. This review aims to provide overview of the key properties of three selected radionuclides, Pb-212, Th-227, At-211, Tb-149. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.
Keywords: Targeted alpha therapy, Pb-212, Th-227, At-211, Tb-149
References
Gudkov SV, Shilyagina NY, Vodeneev VA, Zvyagin AV. Targeted Radionuclide Therapy of Human Tumors. Int J Mol Sci 2015;17:33.
Guerra Liberal FDC, O’Sullivan JM, McMahon SJ, Prise KM. Targeted Alpha Therapy: Current Clinical Applications. Cancer Biother Radiopharm 2020;35:404-417.
Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol 2012;33:573-590.
Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. Cancer Biother Radiopharm 2020;35:425-436.
Westrøm S, Generalov R, Bønsdorff TB, Larsen RH. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution. Nucl Med Biol 2017;51:1-9.
Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, Viswanathan K. Extending human IgG half-life using structure-guided design. MAbs 2018;10:1098-1110.
Mirzadeh S, Kumar K, Gansow OA. The chemical fate of 212Bi-DOTA formed by β-decay of 212Pb(DOTA)2-. Radiochim Acta 1993;60:1-10.
Gregory JN, Moorbath S. Strassmann, 2. physik. Chem. B, 1934, 26, 362. Zimens, 2. physik. Chem. A , 1942, 191, 95. Fliigge and Zimens, 2. physik,” Cornell University Press, 1936.
Zucchini GL, Friedman AM. Isotopic generator for 212Pb and 212Bi. Int J Nucl Med Biol 1982;9:83-84.
Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol 2013;40:592-599.
Li M, Zhang X, Quinn TP, et al. Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot 2017;127:52-60.
Radchenko V, Morgenstern A, Jalilian AR, et al. Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy. J Nucl Med 2021;62:1495-1503.
Li RG, Stenberg VY, Larsen RH. An Experimental Generator for Production of High-Purity 212Pb for Use in Radiopharmaceuticals. J Nucl Med 2023;64:173-176.
Tosato M, Lazzari L, Marco VD. Revisiting Lead(II)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Acid Coordination Chemistry in Aqueous Solutions: Evidence of an Underestimated Thermodynamic Stability. ACS Omega 2022;7:15596-15602.
Xu ZF, Jones MM. Comparative mobilization of lead by chelating agents. Toxicology 1988;53:277-288.
Zaid NRR, Kletting P, Winter G, Prasad V, Beer AJ, Glatting G. A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. Pharmaceutics 2021;13:2132.
Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer. J Labelled Comp Radiopharm 2020;63:129-143.
Kokov KV, Egorova BV, German MN, et al. 212 Pb: Production Approaches and Targeted Therapy Applications. Pharmaceutics 2022;14:189.
Boldyrev PP, Egorova BV, Kokov KV, et al. Physical and chemical processes on the 212Pb radionuclide production for nuclear medicine. J Phys Conf Ser 2018.
Kasten BB, Azure MT, Schoeb TR, Fisher DR, Zinn KR. Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates. Nucl Med Biol 2016;43:391-396.
Delpassand ES, Tworowska I, Esfandiari R, et al. Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med 2022;63:1326-1333.
Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH. Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach. Front Med (Lausanne) 2023;9:1051825.
Li M, Baumhover NJ, Liu D, et al. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics,” Pharmaceutics 2023;15:414.
Frantellizzi V, Cosma L, Brunotti G, et al. Targeted Alpha Therapy with Thorium-227. Cancer Biother Radiopharm 2020;35:437-445.
Ferrier MG, Li Y, Chyan MK, et al. Thorium chelators for Targeted Alpha Therapy: Rapid chelation of thorium-226. J Labelled Comp Radiopharm 2020;63:502-516.
McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341-1351.
Deblonde GJ, Lohrey TD, Booth CH, et al. Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy. Inorg Chem 2018;57:14337-14346.
Hagemann UB, Wickstroem K, Hammer S, et al. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy. Cancer Biother Radiopharm 2020;35:497-510.
Karlsson J, Schatz CA, Wengner AM, et al. Targeted thorium-227 conjugates as treatment options in oncology. Front Med (Lausanne) 2023;9:1071086.
Johnson EL, Turkington TG, Jaszczak RJ, et al. Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995;22:45-54.
Feng Y, Zalutsky MR. Production, purification and availability of 211At: Near term steps towards global access. Nucl Med Biol 2021;100-101:12-23.
Wilbur DS. Enigmatic astatine. Nat Chem 2013;5:246.
Corson DR, MacKenzie KR, Segrè E. Possible Production of Radioactive Isotopes of Element 85. Phys Rev 1940;57:459.
Hamilton JG, Durbin PW, Parrott MW. Accumulation of Astatine211 by Thyroid Gland in Man. Proc Soc Exp Biol Med 1954;86:366-369.
Albertsson P, Bäck T, Bergmark K, et al. Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front Med (Lausanne) 2023;9:1076210.
Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”. Pharmaceutics 2021;13:906.
Natrajan LS, Khoabane NM, Dadds BL, et al. Probing the Structure, Conformation, and Stereochemical Exchange in a Family of Lanthanide Complexes Derived from Tetrapyridyl-Appended Cyclen. Inorg Chem 2010;49:7700-7709.
Chen H, Shi R, Ow H. Predicting Stability Constants for Terbium(III) Complexes with Dipicolinic Acid and 4-Substituted Dipicolinic Acid Analogues using Density Functional Theory. ACS Omega 2019;4:20665-20671.
Müller C, Vermeulen C, Köster U, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem 2017;1:5.
Müller C, Reber J, Haller S, et al. Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals (Basel) 2014;7:353-365.
Beyer GJ, Miederer M, Vranjes-Durić S, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging 2004;31:547-554.
